Tags

Type your tag names separated by a space and hit enter

The role of the renin-angiotensin-aldosterone system in the management of heart failure.
Pharmacotherapy 2000; 20(11 Pt 2):368S-378SP

Abstract

Numerous clinical trials have highlighted the role of the renin-angiotensin-aldosterone (RAA) system in the development and progression of heart failure. Over 30 randomized, controlled trials have evaluated the effects of angiotensin-converting enzyme (ACE) inhibitors on morbidity and mortality in over 7,000 patients with heart failure. Cumulative evidence from these trials shows that these agents significantly reduce mortality and hospitalizations, slow disease progression, and improve exercise tolerance and New York Heart Association class. The Heart Failure Society of America guidelines recommend ACE inhibitors as standard therapy for patients with left ventricular systolic dysfunction. The angiotensin receptor blockers and spironolactone offer alternative and perhaps complimentary mechanisms by which the RAA system may be therapeutically manipulated. The role of these therapies in treating heart failure is discussed.

Authors+Show Affiliations

Schools of Pharmacy, University of North Carolina at Chapel Hill, 27599-7360, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11089708

Citation

Rodgers, J E., and J H. Patterson. "The Role of the Renin-angiotensin-aldosterone System in the Management of Heart Failure." Pharmacotherapy, vol. 20, no. 11 Pt 2, 2000, 368S-378S.
Rodgers JE, Patterson JH. The role of the renin-angiotensin-aldosterone system in the management of heart failure. Pharmacotherapy. 2000;20(11 Pt 2):368S-378S.
Rodgers, J. E., & Patterson, J. H. (2000). The role of the renin-angiotensin-aldosterone system in the management of heart failure. Pharmacotherapy, 20(11 Pt 2), 368S-378S.
Rodgers JE, Patterson JH. The Role of the Renin-angiotensin-aldosterone System in the Management of Heart Failure. Pharmacotherapy. 2000;20(11 Pt 2):368S-378S. PubMed PMID: 11089708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of the renin-angiotensin-aldosterone system in the management of heart failure. AU - Rodgers,J E, AU - Patterson,J H, PY - 2000/11/23/pubmed PY - 2001/3/3/medline PY - 2000/11/23/entrez SP - 368S EP - 378S JF - Pharmacotherapy JO - Pharmacotherapy VL - 20 IS - 11 Pt 2 N2 - Numerous clinical trials have highlighted the role of the renin-angiotensin-aldosterone (RAA) system in the development and progression of heart failure. Over 30 randomized, controlled trials have evaluated the effects of angiotensin-converting enzyme (ACE) inhibitors on morbidity and mortality in over 7,000 patients with heart failure. Cumulative evidence from these trials shows that these agents significantly reduce mortality and hospitalizations, slow disease progression, and improve exercise tolerance and New York Heart Association class. The Heart Failure Society of America guidelines recommend ACE inhibitors as standard therapy for patients with left ventricular systolic dysfunction. The angiotensin receptor blockers and spironolactone offer alternative and perhaps complimentary mechanisms by which the RAA system may be therapeutically manipulated. The role of these therapies in treating heart failure is discussed. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/11089708/The_role_of_the_renin_angiotensin_aldosterone_system_in_the_management_of_heart_failure_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0277-0008&date=2000&volume=20&issue=11 Pt 2&spage=368S DB - PRIME DP - Unbound Medicine ER -